Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4133207?pdf=render |
| _version_ | 1798043332553736192 |
|---|---|
| author | Yutaka Fujiwara Masanori Toyoda Naoko Chayahara Naomi Kiyota Takanobu Shimada Yoshinori Imamura Toru Mukohara Hironobu Minami |
| author_facet | Yutaka Fujiwara Masanori Toyoda Naoko Chayahara Naomi Kiyota Takanobu Shimada Yoshinori Imamura Toru Mukohara Hironobu Minami |
| author_sort | Yutaka Fujiwara |
| collection | DOAJ |
| description | PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was to investigate the effects of the mild CYP3A4 inhibitor aprepitant on the pharmacokinetics of orally administered controlled-release (CR) oxycodone. METHOD: This study design was an open-label, single-sequence with two phases in cancer patients with pain who continued to be administered orally with multiple doses of CR oxycodone every 8 or 12 hours. Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning). The steady-state trough concentrations (Css) were measured from day 1 to day 3. RESULTS: Aprepitant increased the area under the plasma concentration-time curve (AUC0-8) of oxycodone by 25% (p<0.001) and of oxymorphone by 34% (p<0.001), as well as decreased the AUC0-8 of noroxycodone by 14% (p<0.001). Moreover, aprepitant increased Css of oxycodone by 57% (p = 0.001) and of oxymorphone by 36% (p<0.001) and decreased Css of noroxycodone by 24% (p = 0.02) at day 3 compared to day 1. CONCLUSIONS: The clinical use of aprepitant in patients receiving multiple doses of CR oxycodone for cancer pain significantly altered plasma concentration levels, but would not appear to need modification of the CR oxycodone dose. TRIAL REGISTRATION: UMIN.ac.jp UMIN000003580. |
| first_indexed | 2024-04-11T22:47:42Z |
| format | Article |
| id | doaj.art-0a282b5555004faa8cb5049a8333da2f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T22:47:42Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0a282b5555004faa8cb5049a8333da2f2022-12-22T03:58:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10421510.1371/journal.pone.0104215Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Yutaka FujiwaraMasanori ToyodaNaoko ChayaharaNaomi KiyotaTakanobu ShimadaYoshinori ImamuraToru MukoharaHironobu MinamiPURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was to investigate the effects of the mild CYP3A4 inhibitor aprepitant on the pharmacokinetics of orally administered controlled-release (CR) oxycodone. METHOD: This study design was an open-label, single-sequence with two phases in cancer patients with pain who continued to be administered orally with multiple doses of CR oxycodone every 8 or 12 hours. Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning). The steady-state trough concentrations (Css) were measured from day 1 to day 3. RESULTS: Aprepitant increased the area under the plasma concentration-time curve (AUC0-8) of oxycodone by 25% (p<0.001) and of oxymorphone by 34% (p<0.001), as well as decreased the AUC0-8 of noroxycodone by 14% (p<0.001). Moreover, aprepitant increased Css of oxycodone by 57% (p = 0.001) and of oxymorphone by 36% (p<0.001) and decreased Css of noroxycodone by 24% (p = 0.02) at day 3 compared to day 1. CONCLUSIONS: The clinical use of aprepitant in patients receiving multiple doses of CR oxycodone for cancer pain significantly altered plasma concentration levels, but would not appear to need modification of the CR oxycodone dose. TRIAL REGISTRATION: UMIN.ac.jp UMIN000003580.http://europepmc.org/articles/PMC4133207?pdf=render |
| spellingShingle | Yutaka Fujiwara Masanori Toyoda Naoko Chayahara Naomi Kiyota Takanobu Shimada Yoshinori Imamura Toru Mukohara Hironobu Minami Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PLoS ONE |
| title | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
| title_full | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
| title_fullStr | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
| title_full_unstemmed | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
| title_short | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
| title_sort | effects of aprepitant on the pharmacokinetics of controlled release oral oxycodone in cancer patients |
| url | http://europepmc.org/articles/PMC4133207?pdf=render |
| work_keys_str_mv | AT yutakafujiwara effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT masanoritoyoda effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT naokochayahara effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT naomikiyota effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT takanobushimada effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT yoshinoriimamura effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT torumukohara effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients AT hironobuminami effectsofaprepitantonthepharmacokineticsofcontrolledreleaseoraloxycodoneincancerpatients |